MoonLake Immunotherapeutics
MLTX10.630USD
+0.340+3.30%
Fechamento 11/07, 16:00（ET）Cotações atrasadas em 15 min
677.18MValor de mercado
PerdaP/L TTM
Mais detalhes de MoonLake Immunotherapeutics Empresa
MoonLake Immunotherapeutics, formerly known as Helix Acquisition Corp, is a Switzerland-based company engaged in the healthcare industry. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The Company develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.
Informações de MoonLake Immunotherapeutics
Código da empresaMLTX
Nome da EmpresaMoonLake Immunotherapeutics
Data de listagemOct 20, 2020
CEODr. Jorge Santos Da Silva
Número de funcionários100
Tipo de títulosOrdinary Share
Fim do ano fiscalOct 20
EndereçoDorfstrasse 29
CidadeZUG
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísSwitzerland
Código postal6300
Telefone41415108022
Sitehttps://moonlaketx.com/
Código da empresaMLTX
Data de listagemOct 20, 2020
CEODr. Jorge Santos Da Silva
Executivos da empresa MoonLake Immunotherapeutics
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Kristian Reich
Dr. Kristian Reich
Chief Scientific Officer
Chief Scientific Officer
3.13M
+1.59%
Dr. Jorge Santos Da Silva
Dr. Jorge Santos Da Silva
Chief Executive Officer, Director
Chief Executive Officer, Director
3.08M
--
Mr. Matthias Bodenstedt
Mr. Matthias Bodenstedt
Chief Financial Officer
Chief Financial Officer
627.54K
+1.76%
Mr. Simon Sturge
Mr. Simon Sturge
Independent Chairman of the Board
Independent Chairman of the Board
171.98K
--
Dr. Andrew J. Phillips
Dr. Andrew J. Phillips
Independent Director
Independent Director
--
--
Dr. Atif Khan
Dr. Atif Khan
Director - Strategic Planning and Projects
Director - Strategic Planning and Projects
--
--
Ms. Catherine Moukheibir
Ms. Catherine Moukheibir
Independent Director
Independent Director
--
--
Dr. Ramnik Xavier
Dr. Ramnik Xavier
Independent Director
Independent Director
--
--
Mr. Spike N. Loy, J.D.
Mr. Spike N. Loy, J.D.
Independent Director
Independent Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Kristian Reich
Dr. Kristian Reich
Chief Scientific Officer
Chief Scientific Officer
3.13M
+1.59%
Dr. Jorge Santos Da Silva
Dr. Jorge Santos Da Silva
Chief Executive Officer, Director
Chief Executive Officer, Director
3.08M
--
Mr. Matthias Bodenstedt
Mr. Matthias Bodenstedt
Chief Financial Officer
Chief Financial Officer
627.54K
+1.76%
Mr. Simon Sturge
Mr. Simon Sturge
Independent Chairman of the Board
Independent Chairman of the Board
171.98K
--
Dr. Andrew J. Phillips
Dr. Andrew J. Phillips
Independent Director
Independent Director
--
--
Dr. Atif Khan
Dr. Atif Khan
Director - Strategic Planning and Projects
Director - Strategic Planning and Projects
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: ter, 4 de nov
Atualizado em: ter, 4 de nov
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
BVF Partners L.P.
27.67%
Fidelity Management & Research Company LLC
7.44%
Avoro Capital Advisors LLC
5.81%
Reich (Kristian)
4.38%
Santos da Silva (Jorge)
4.31%
Outro
50.37%
Investidores
Investidores
Proporção
BVF Partners L.P.
27.67%
Fidelity Management & Research Company LLC
7.44%
Avoro Capital Advisors LLC
5.81%
Reich (Kristian)
4.38%
Santos da Silva (Jorge)
4.31%
Outro
50.37%
Tipos de investidores
Investidores
Proporção
Hedge Fund
41.51%
Investment Advisor
20.11%
Investment Advisor/Hedge Fund
17.19%
Individual Investor
11.03%
Research Firm
2.11%
Venture Capital
1.30%
Bank and Trust
0.07%
Pension Fund
0.05%
Outro
6.62%
Participação acionária institucional
Atualizado em: qua, 1 de out
Atualizado em: qua, 1 de out
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q3
336
52.26M
73.22%
-13.87M
2025Q2
326
71.15M
112.06%
-8.45M
2025Q1
329
71.47M
112.59%
-8.98M
2024Q4
308
74.57M
117.86%
+1.09M
2024Q3
292
73.42M
116.42%
+551.38K
2024Q2
282
72.21M
114.78%
+1.82M
2024Q1
274
70.82M
112.58%
-306.27K
2023Q4
260
64.82M
107.09%
-2.17M
2023Q3
219
60.33M
114.64%
-5.55M
2023Q2
175
60.28M
100.54%
+9.44M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
BVF Partners L.P.
19.75M
31.1%
--
--
Jun 30, 2025
Fidelity Management & Research Company LLC
5.31M
8.36%
-114.00K
-2.10%
Jun 30, 2025
Avoro Capital Advisors LLC
4.15M
6.54%
+1.38M
+49.81%
Jun 30, 2025
Reich (Kristian)
3.13M
4.93%
+48.98K
+1.59%
Sep 02, 2025
Santos da Silva (Jorge)
3.08M
4.85%
--
--
Mar 15, 2025
T. Rowe Price Associates, Inc.
2.61M
4.12%
-360.60K
-12.13%
Jun 30, 2025
Cormorant Asset Management, LP
1.99M
3.14%
-6.50M
-76.52%
Sep 30, 2025
Citadel Advisors LLC
1.67M
2.64%
+195.41K
+13.22%
Jun 30, 2025
Westfield Capital Management Company, L.P.
1.26M
1.98%
-175.39K
-12.22%
Jun 30, 2025
Goldman Sachs & Company, Inc.
1.26M
1.98%
-19.32K
-1.52%
Jun 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: qui, 6 de nov
Atualizado em: qui, 6 de nov
Nome
Proporção
ALPS Medical Breakthroughs ETF
0.27%
Global X Guru Index ETF
0.16%
Goldman Sachs Future Health Care Equity ETF
0.12%
Virtus LifeSci Biotech Clinical Trials ETF
0.12%
JPMorgan Healthcare Leaders ETF
0.03%
First Trust IPOX Europe Equity Opportunities ETF
0.02%
JPMorgan BetaBuilders US Small Cap Equity ETF
0.01%
John Hancock Multifactor Small Cap ETF
0.01%
iShares ESG Aware MSCI USA Small-Cap ETF
0.01%
Fidelity Blue Chip Growth ETF
0.01%
Ver Mais
ALPS Medical Breakthroughs ETF
Proporção0.27%
Global X Guru Index ETF
Proporção0.16%
Goldman Sachs Future Health Care Equity ETF
Proporção0.12%
Virtus LifeSci Biotech Clinical Trials ETF
Proporção0.12%
JPMorgan Healthcare Leaders ETF
Proporção0.03%
First Trust IPOX Europe Equity Opportunities ETF
Proporção0.02%
JPMorgan BetaBuilders US Small Cap Equity ETF
Proporção0.01%
John Hancock Multifactor Small Cap ETF
Proporção0.01%
iShares ESG Aware MSCI USA Small-Cap ETF
Proporção0.01%
Fidelity Blue Chip Growth ETF
Proporção0.01%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
